Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/yybyuta-738   Repeated shots of Regeneron’s antibody cocktail REGEN-COV reduced the risk of a CoVid infection by 92.4% for unvaccinated persons.  Regeneron-sponsored doubled-blinded, placebo controlled trials in Texas and Ohio studied 969 uninfected and unvaccinated subjects receiving 6 monthly shots of antibody compared with a control group of 240 subjects receiving placebo injections.   The monthly antibody injections were significantly protective even for those persons with complicating medical issues.  Injection site reactions occurred in 37% of the treatment group but the majority were mild and resolved within 4 days of injection.  There were no significant immunological reactions mounted against the injected antibodies that would limit their protection.   This Regeneron cocktail has been successfully used as an intravenous injection to treat hospitalized patients with severe CoVid.  This new study shows that subcutaneous shots of the same drug can successfully prevent CoVid.